RE-BVS – Piemonte Repository

Sfoglia per AUTORE
PANTANO F
Collezione AO Ordine Mauriziano

Items : 3

Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2022 Apr;71(4):865-874. doi: 10.1007/s00262-021-03045-9. Epub 2021 Aug 31

2022
AO Ordine Mauriziano

Marconcini R; Intagliata S; Audisio M; Lai E; Aprile G; Buti S; Ghidini M; Macrini S; Inno A; Di Marino P; Tuzi A; Nicolardi L; Occhipinti MA; Pergolesi F; Veltri E; Adamo V; Filetti M; Ficorella C; Pantano F; Citarella F; Falcone A; Bossi P; Di Maio M; Scartozzi M; Di Noia V; Calvetti L; Bersanelli M; Grossi F; Gori S; et alii...

Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7). in American journal of clinical oncology / Am J Clin Oncol. 2021 Mar 1;44(3):121-125. doi: 10.1097/COC.0000000000000791.

2021
AO Ordine Mauriziano

Mini E; Grillone F; Mucciarini C; Fornarini G; Soraru' M; Verzoni E; Sbrana A; Di Lorenzo G; De Vivo R; Bersanelli M; Buti S; Naglieri E; Bimbatti D; Maruzzo M; Casadei C; De Lisi D; Pantano F; De Giorgi U; Stellato M; Santini D; Vignani F; Attademo L; Pignata S; Procopio G;

Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). in Frontiers in oncology / Front Oncol. 2021 Jun 8;11:682449. doi: 10.3389/fonc.2021.682449. eCollection 2021.

2021
AO Ordine Mauriziano

Mucciarini C; Vignani F; De Vivo R; Napolitano A; Buti S; Naglieri E; Di Lorenzo G; Soraru M; Sbrana A; Maruzzo M; Fornarini G; Casadei C; Pantano F; De Giorgi U; Verzoni E; Santini D; Stellato M; Grillone F; Roviello G; Di Napoli M; Procopio G;